Evaxion schedules November immune update after 2025 melanoma readout

New immune data will reach investors on Nov. 6 as Evaxion A/S NASDAQEVAX plans an oral presentation from its EVX-01 melanoma study at the Society for Immunotherapy of Cancer meeting. The reference point is a two-year analysis first reported on Oct. 17, 2025, when 12 of 16 patients had responded to the vaccine plus pembrolizumab.

The Oct. 2 notice says Evaxion will examine broader immune-system effects of EVX-01 with pembrolizumab beyond vaccine-specific T-cell responses. It sets a poster presentation for Nov. 7 and points to a separate three-year clinical update at the European Society for Medical Oncology congress on Oct. 24. The notice contains no new response rate or safety results.

Evaxion is a Denmark-based clinical-stage developer that uses its AI platform to design personalized immunotherapies for cancer.

On Friday, the NASDAQEVAX quote showed shares at US$3.23 as of 9:30:01 a.m. EDT. That opening print does not show how the stock traded later in the session.

The 2025 Filing Said the Primary Endpoint Was Not Formally Analyzed

Evaxion's October 2025 filing reported a 75 per cent objective response rate after two years, including four complete responses. The rate had been 69 per cent after one year. Eleven of the 12 responders were still responding at 24 months, which the company described as 92 per cent durability; it reported no relapses at that cutoff.

The study group received the personalized vaccine with pembrolizumab, and the filing did not report a concurrent pembrolizumab-only comparison or a p value. Evaxion said it did not formally analyze the planned primary endpoint, improvement in response category, because enrollment fell below the original protocol. The company reported that 54 per cent moved to a better response category, but the primary analysis remained undone.

Evaxion described the combination treatment as well tolerated in its October 2025 filing, without an adverse-event breakdown in that release. It also said progression-free and overall survival were not yet reportable because most patients remained in response at the cutoff.

"The new data will reflect the systemic immunomodulatory effects of EVX-01 plus pembrolizumab beyond vaccine-specific T-cell responses using comprehensive immune profiling," Evaxion said in its Oct. 2 release.

The October 2025 filing put the immune response to vaccine targets at 81 per cent, while the Oct. 2 release cites 86 per cent. Neither document provides matching target denominators for that comparison, so the difference alone does not establish stronger immune activity. The planned presentation may show how Evaxion measured the wider immune effects.

Patients received EVX-01 alone during the third year of follow-up, according to the Oct. 2 release. Its Oct. 24 presentation is therefore the next scheduled look at response durability after pembrolizumab was removed. In its 2025 filing, Evaxion said further clinical development would take place only with a partner.

Moderna Lists a Phase 3 Melanoma Program

Moderna, Inc. NASDAQMRNA listed its personalized mRNA-4157 program for adjuvant melanoma in Phase 3 as of May 28, 2026. Its metastatic melanoma program was listed in Phase 2.

For sector context, the iShares Biotechnology ETF NASDAQIBB stood at US$210.53 at Wednesday's close, as of 4:00:01 p.m. EDT on its quote page. Evaxion's next data releases will show whether the small cohort's responses have persisted and whether its immune readout adds evidence relevant to a partner-led trial.

Read more: Immunome gains FDA IND clearance for IM-1340 solid tumour study

Read more: Summit Therapeutics plans Phase III Datroway breast cancer trial

The Oct. 24 ESMO presentation will show the three-year clinical follow-up after patients spent the final year on EVX-01 alone. The Nov. 6 oral and Nov. 7 poster sessions at SITC will then disclose the new immune analyses that Evaxion has scheduled.